• 1
    Schroder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
  • 2
    Roobol MJ, Kerkhof M, Schroder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2009; 56: 584-591.
  • 3
    Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11: 725-732.
  • 4
    Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95: 868-878.
  • 5
    Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101: 374-383.
  • 6
    Postma R, van Marion R, van Duin M, et al. Array-based genomic analysis of screen-detected Gleason score 6 and 7 prostatic adenocarcinomas. Anticancer Res. 2006; 26: 1193-1200.
  • 7
    Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005; 294: 66-70.
  • 8
    Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003; 170: 1792-1797.
  • 9
    Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007; 177: 107-112; discussion 112.
  • 10
    Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schroder FH. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer. 2007; 110: 2218-2221.
  • 11
    Dong F, Kattan MW, Steyerberg EW, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol. 2008; 180: 150-154; discussion 154.
  • 12
    Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271: 368-374.
  • 13
    Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998; 160( 6 pt 2): 2407-2411.
  • 14
    Williams SB, Salami S, Regan MM, et al. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network (EDRN) prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial (PCPT). Cancer. 2011; 118: 2651-2658.
  • 15
    Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010; 57: 79-85.
  • 16
    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215-224.
  • 17
    Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006; 98: 1128-1133.